Patents by Inventor Maximiliano Vasquez

Maximiliano Vasquez has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Antithrombotic agent and humanized anti-von Willebrand factor monoclonal antibody
    Patent number: 7138116
    Abstract: Anti-thrombotic agents containing humanized antibodies which bind to von Willebrand factor.
    Type: Grant
    Filed: November 7, 2002
    Date of Patent: November 21, 2006
    Assignee: Ajinomoto Co., Inc.
    Inventors: Man Sung Co, Maximiliano Vasquez
  • Humanized immunoglobulin reactive with B7-2 and methods of treatment therewith
    Publication number: 20060251645
    Abstract: The invention relates to a humanized anti-B7-2 antibody that comprises a variable region of nonhuman origin and at least a portion of an immunoglobulin of human origin. The invention also pertains to methods of treatment for various autoimmune diseases, transplant rejection, inflammatory disorders and infectious diseases by administering humanized anti-B7-2 and/or anti-B7-1 antibodies.
    Type: Application
    Filed: December 5, 2005
    Publication date: November 9, 2006
    Inventors: Man Co, Maximiliano Vasquez, Beatriz Carreno, Abbie Celniker, Mary Collins, Samuel Goldman, Gary Gray, Andrea Knight, Denise O'Hara, Bonita Rup, Geertruida Veldman
  • Humanized antibodies that sequester abeta peptide
    Publication number: 20060039906
    Abstract: A method to treat conditions characterized by formation of amyloid plaques both prophylactically and therapeutically is described. The method employs humanized antibodies which sequester soluble A? peptide from human biological fluids or which preferably specifically bind an epitope contained within position 13-28 of the amyloid beta peptide A?.
    Type: Application
    Filed: September 12, 2005
    Publication date: February 23, 2006
    Inventors: David Holtzman, Ronald DeMattos, Kelly Bales, Steven Paul, Naoya Tsurushita, Maximiliano Vasquez
  • Method of transplanting cells by contacting donor cells with B7-1-and B7-2-specific immunoglobulins
    Patent number: 6984383
    Abstract: The invention relates to a humanized anti-B7-2 antibody that comprises a variable region of nonhuman origin and at least a portion of an immunoglobulin of human origin. The invention also pertains to methods of treatment for various autoimmune diseases, transplant rejection, inflammatory disorders and infectious diseases by administering humanized anti-B7-2 and/or anti-B7-1 antibodies.
    Type: Grant
    Filed: July 27, 2000
    Date of Patent: January 10, 2006
    Assignee: Genetics Institute, LLC
    Inventors: Man Sung Co, Maximiliano Vasquez, Beatriz Carreno, Abbie Cheryl Celniker, Mary Collins, Samuel Goldman, Gary S. Gray, Andrea Knight, Denise O'Hara, Bonita Rup, Geertruida M. Veldman
  • Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
    Publication number: 20050276799
    Abstract: The present invention provides for a modified antibody of class IgG, in which at least one amino acid from the heavy chain constant region selected from the group consisting of amino acid residues 250, 314, and 428 is substituted with another amino acid which is different from that present in the unmodified antibody, thereby altering the binding affinity for FcRn and/or the serum half-life in comparison to the unmodified antibody.
    Type: Application
    Filed: April 8, 2005
    Publication date: December 15, 2005
    Inventors: Paul Hinton, Naoya Tsurushita, J. Tso, Maximiliano Vasquez
  • Humanized immunoglobulin reactive with B7-2 and methods of treatment therewith
    Patent number: 6972125
    Abstract: The invention relates to a humanized anti-B7-2 antibody that comprises a variable region of nonhuman origin and at least a portion of an immunoglobulin of human origin. The invention also pertains to methods of treatment for various autoimmune diseases, transplant rejection, inflammatory disorders and infectious diseases by administering humanized anti-B7-2 and/or anti-B7-1 antibodies.
    Type: Grant
    Filed: February 12, 1999
    Date of Patent: December 6, 2005
    Assignee: Genetics Institute, LLC
    Inventors: Man Sung Co, Maximiliano Vasquez, Beatriz Carreno, Abbie Cheryl Celniker, Mary Collins, Samuel Goldman, Gary S. Gray, Andrea Knight, Denise O'Hara, Bonita Rup, Geertruida M. Veldman
  • Humanized immunoglobulin reactive with B7 molecules and methods of treatment therewith
    Publication number: 20050208042
    Abstract: The invention relates to humanized anti-B7-2 and anti-B7-1 antibodies, wherein each comprise a variable region of non-human origin and at least a portion of an immunoglobulin of human origin. The invention also pertains to methods of treatment for various autoimmune diseases, transplant rejection, inflammatory disorders and infectious diseases by administering humanized anti-B7-2 and/or anti-B7-1 antibodies.
    Type: Application
    Filed: November 12, 2004
    Publication date: September 22, 2005
    Inventors: Man Co, Maximiliano Vasquez, Beatriz Carreno, Abbie Celniker, Mary Collins, Samuel Goldman, Gary Gray, Andrea Knight, Denise O'Hara, Bonita Rup, Geertruida Veldman
  • Methods of treating thrombotic diseases with von willebrand factor specific antibodies
    Publication number: 20050197494
    Abstract: Anti-thrombotic agents containing humanized antibodies which bind to von Willebrand factor.
    Type: Application
    Filed: February 28, 2005
    Publication date: September 8, 2005
    Applicant: Ajinomoto Co., Inc.
    Inventors: Man Co, Maximiliano Vasquez
  • Humanized immunoglobulin reactive with B7 therewith
    Patent number: 6913747
    Abstract: The invention relates to humanized anti-B7-2 and anti-B7-1 antibodies, wherein each comprise a variable region of non-human origin and at least a portion of an immunoglobulin of human origin. The invention also pertains to methods of treatment for various autoimmune diseases, transplant rejection, inflammatory disorders and infectious diseases by administering humanized anti-B7-2 and/or anti-B7-1 antibodies.
    Type: Grant
    Filed: June 24, 1999
    Date of Patent: July 5, 2005
    Inventors: Man Sung Co, Maximiliano Vasquez, Beatriz Carreno, Abbie Cheryl Celniker, Mary Collins, Samuel Goldman, Gary S. Gray, Andrea Knight, Denise O'Hara, Bonita Rup, Geertruida M. Veldman
  • Humanized antibodies
    Publication number: 20050142131
    Abstract: Humanized forms of mouse antibody 10D5 that retain the binding properties of mouse 10D5 are disclosed. Also disclosed closed are processes for making the humanized antibody, intermediates for making the humanized antibodies, including, nucleotide sequences, vectors, transformed host cells, and methods of using the humanized antibody to treat, prevent, alleviate, reverse, or otherwise ameliorate symptoms or pathology or both, that are associated with Down's syndrome or pre-clinical or clinical Alzheimer's disease or cerebral amyloid angiopathy.
    Type: Application
    Filed: April 26, 2002
    Publication date: June 30, 2005
    Inventors: Paul Hinton, Maximiliano Vasquez
  • Humanized antibodies
    Publication number: 20050090648
    Abstract: Humanized forms of mouse antibody 3D6 that retain the binding properties of mouse 3D6 are disclosed. Also disclosed are processes for making the humanized antibody, intermediates for making the humanized antibodies, including, nucleotide sequences, vectors, transformed host cells, and methods of using the humanized antibody to treat, prevent, alleviate, reverse, or otherwise ameliorate symptoms or pathology or both, that are associated with Down's syndrome or pre-clinical or clinical Alzheimer's disease or cerebral amyloid angiopathy.
    Type: Application
    Filed: April 26, 2002
    Publication date: April 28, 2005
    Inventors: Naoya Tsurushita, Maximiliano Vasquez
  • Interleukin-1 beta antibodies
    Publication number: 20050075488
    Abstract: The present invention encompasses high affinity antibodies that neutralize IL-1? activity in vivo. These antibodies can be used to treat various diseases such as rheumatoid arthritis and osteoarthritis.
    Type: Application
    Filed: July 18, 2002
    Publication date: April 7, 2005
    Inventors: Stuart Bright, Audrey Jia, Stuart Kuhstoss, Joseph Vincent Manetta, Naoya Tsurushita, Maximiliano Vasquez
  • Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
    Publication number: 20050032114
    Abstract: The present invention provides for a modified antibody of class IgG, in which at least one amino acid from the heavy chain constant region selected from the group consisting of amino acid residues 250, 314, and 428 is substituted with another amino acid which is different from that present in the unmodified antibody, thereby altering the binding affinity for FcRn and/or the serum half-life in comparison to the unmodified antibody.
    Type: Application
    Filed: October 15, 2003
    Publication date: February 10, 2005
    Inventors: Paul Hinton, Naoya Tsurushita, J. Tso, Maximiliano Vasquez
  • Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
    Publication number: 20050014934
    Abstract: The present invention provides for a modified antibody of class IgG, in which at least one amino acid from the heavy chain constant region selected from the group consisting of amino acid residues 250, 314, and 428 is substituted with another amino acid which is different from that present in the unmodified antibody, thereby altering the binding affinity for FcRn and/or the serum half-life in comparison to the unmodified antibody.
    Type: Application
    Filed: April 9, 2004
    Publication date: January 20, 2005
    Inventors: Paul Hinton, Naoya Tsurushita, J. Tso, Maximiliano Vasquez
  • Humanized chicken antibodies
    Publication number: 20040260068
    Abstract: The present invention concerns chicken antibodies and humanized chicken antibodies and the method of making such antibodies. In a particular embodiment, it provides humanized chicken antibodies that bind to or neutralize human and/or mouse proteins, such as IL-12 or L-selectin. It also provides the method for the prevention or treatment of autoimmune diseases by using such antibodies.
    Type: Application
    Filed: February 26, 2004
    Publication date: December 23, 2004
    Inventors: Naoya Tsurushita, Shankar Kumar, Maximiliano Vasquez
  • Humanized immunoglobulin reactive with b7-2 and methods of treatment therewith
    Patent number: 6827934
    Abstract: The invention relates to a humanized anti-B7-2 antibody that comprises a variable region of nonhuman origin and at least a portion of an immunoglobulin of human origin. The invention also pertains to methods of treatment for various autoimmune diseases, transplant rejection, inflammatory disorders and infectious diseases by administering humanized anti-B7-2 and/or anti-B7-1 antibodies.
    Type: Grant
    Filed: July 27, 2000
    Date of Patent: December 7, 2004
    Assignee: Genetics Institute, LLC
    Inventors: Man Sung Co, Maximiliano Vasquez, Beatriz Carreno, Abbie Cheryl Celniker, Mary Collins, Samuel Goldman, Andrea Knight, Denise O'Hara, Bonita Rup, Geertruida M. Veldman, Gary S. Gray
  • Silenced anti-cd28 antibodies and use thereof
    Publication number: 20040116675
    Abstract: The present invention provides anti-CD28 antibodies which are defective in mitogenic activity (silenced anti-CD28 antibodies), methods of producing, compositions containing the antibody and methods of immunosuppression, inducing T-cell tolerance and treating organ and/or tissue transplant rejections.
    Type: Application
    Filed: December 24, 2003
    Publication date: June 17, 2004
    Inventors: J. Jun Tso, Paul Hinton, Maximiliano Vasquez, Kouichi Tamura, Yasuyuki Higashi, Nobuo Seki, Hirotsugu Ueda
  • Humanized antibodies that sequester Abeta peptide
    Publication number: 20040043418
    Abstract: A method to treat conditions characterized by formation of amyloid plaques both prophylactically and therapeutically is described. The method employs humanized antibodies which sequester soluble A&bgr; peptide from human biological fluids or which preferably specifically bind an epitope contained within position 13-28 of the amyloid beta peptide A&bgr;.
    Type: Application
    Filed: August 21, 2002
    Publication date: March 4, 2004
    Inventors: David M. Holtzman, Ronald DeMattos, Kelly R. Bales, Steven M. Paul, Naoya Tsurushita, Maximiliano Vasquez
  • Anti-CCR5 antibody
    Publication number: 20030228306
    Abstract: The invention is directed an anti-CCR5 antibody which comprises (i) two light chains, each light chain comprising the expression product of a plasmid designated pVK:HuPRO140-VK (ATCC Deposit Designation PTA-4097), and (ii) two heavy chains, each heavy chain comprising an expression product of either a plasmid designated pVg1:HuPRO140 HG2-VH (ATCC Deposit Designation PTA-4098) or a plasmid designated pVg1:HuPRO140 (mutB+D+I)-VH (ATCC Deposit Designation PTA-4099) or a fragment thereof which binds to CCR5 on the surface of a human cell.
    Type: Application
    Filed: February 21, 2003
    Publication date: December 11, 2003
    Inventors: William C. Olson, Paul J. Maddon, Naoya Tsurushita, Paul R. Hinton, Maximiliano Vasquez
  • Antithrombotic agent and humanized anti-von willebrand factor monoclonal antibody
    Publication number: 20030180293
    Abstract: Anti-thrombotic agents containing humanized antibodies which bind to von Willebrand factor.
    Type: Application
    Filed: November 7, 2002
    Publication date: September 25, 2003
    Applicant: AJINOMOTO CO. INC
    Inventors: Man Sung Co, Maximiliano Vasquez